Associations - Squamous Cell Carcinoma of Head and Neck

No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPF Sensitive: A1 - Approval TPF Sensitive : A1
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative PD-L1 negative	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	ADX-2191 Sensitive: A2 - Guideline ADX-2191 Sensitive : A2
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 expression PD-L1 expression	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + nivolumab Sensitive: A2 - Guideline pembrolizumab + nivolumab Sensitive : A2
No biomarker No biomarker	Squamous Cell Carcinoma of Head and Neck SCCHN	AT-406 Sensitive: B - Late Trials AT-406 Sensitive : B
CDKN2A negative CDKN2A negative	Squamous Cell Carcinoma of Head and Neck SCCHN	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
HRAS mutation HRAS mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES